Northwire Canada EditionSaturday, October 17, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0%
Earnings

BioSyent Releases Financial Results for Q3 and YTD 2025

By The Northwire Desk — AI Analysis Nov 20, 2025 · 17:30 RX · 10.72 BioSyent Inc.
RX · Price

Executive Summary

  • BioSyent Inc. released its financial results for the third quarter and year-to-date period ended September 30, 2025, reporting significant growth across all business segments.
  • Total Company Sales increased by 28% in Q3 2025 compared to Q3 2024, reaching CAD 12.2 million, while EBITDA rose 27% to CAD 3.6 million.
  • The company declared a subsequent cash dividend of $0.05 per common share, payable on December 15, 2025, and reported strong balance sheet metrics including a 47% increase in cash and short-term investments.

Key Details

  • Q3 2025 Financial Performance:
    • Total Company Sales: CAD 12,221,804 (+28% vs Q3 2024).
    • EBITDA: CAD 3,632,399 (+27% vs Q3 2024).
    • Net Income After Taxes (NIAT): CAD 2,682,340 (+16% vs Q3 2024).
    • Fully Diluted EPS: CAD 0.23 (+19% vs Q3 2024).
    • EBITDA Margin: 30% of sales.
  • Year-to-Date (YTD) 2025 Performance:
    • Total Company Sales: CAD 33,380,060 (+27% vs YTD 2024).
    • EBITDA: CAD 9,594,195 (+35% vs YTD 2024).
    • Net Income After Taxes (NIAT): CAD 7,020,444 (+24% vs YTD 2024).
    • Fully Diluted EPS: CAD 0.61 (+28% vs YTD 2024).
    • EBITDA Margin: 29% of sales.
  • Trailing Twelve Months (TTM) Performance:
    • Total Company Sales: CAD 42,176,744 (+22% vs TTM Sept 30, 2024).
    • EBITDA: CAD 11,835,307 (+35% vs TTM Sept 30, 2024).
    • Net Income After Taxes (NIAT): CAD 8,633,638 (+21% vs TTM Sept 30, 2024).
    • Return on Average Equity: 22% (vs 20% in prior year).
  • Segment Sales Breakdown (Q3 2025):
    • Canadian Pharma Sales: CAD 9,864,254 (+19%).
    • International Pharma Sales: CAD 1,153,742 (+94%).
    • Legacy Business Sales: CAD 1,203,808 (+83%).
  • Balance Sheet Highlights (As of Sept 30, 2025):
    • Cash, cash equivalents, and short-term investments: CAD 23,395,434 (+47% vs Dec 31, 2024).
    • Total Assets: CAD 47,785,381 (+16% vs Dec 31, 2024).
    • Total Equity: CAD 39,902,869 (+14% vs Dec 31, 2024).
  • Corporate Actions:
    • Repurchased 19,500 common shares for cancellation under a Normal Course Issuer Bid (NCIB) during YTD 2025.
    • Paid quarterly cash dividends of $0.05 per share on March 14, June 13, and September 15, 2025.
    • Declared subsequent cash dividend of $0.05 per common share to be paid on December 15, 2025.

Notable Quotes

  • “BioSyent delivered strong third quarter financial results... Each of our three businesses performed well during the quarter, with total Company sales increasing by 28% overall. Though we experienced some gross margin compression on changes in sales mix, our overall EBITDA¹ margin in Q3 2025 remained consistent with the comparative period at 30% to sales as operating expenses were maintained in proportion to sales growth.” — René Goehrum, President and CEO
Read the original news release →

More from BioSyent Inc.

May 19, 2026 · 09:52

BioSyent enters endocrinology with sole-source liquid levothyroxine — a niche launch, but the upside hinges on Tibella/FeraMAX still doing the heavy lifting.

Regulatory May 14, 2026 · 18:00

BioSyent’s Q1 Shows Oral Science Deal Paying Off, but Pharma Core Holds Steady

Earnings Mar 19, 2026 · 17:30

BioSyent Releases Financial Results for Fourth Quarter and Full Year 2025

Earnings Mar 12, 2026 · 17:30

BioSyent Schedules Fourth Quarter and Full Year 2025 Earnings Release for March 19, 2026

Earnings Mar 02, 2026 · 21:07

BioSyent closes Oral Science acquisition, grants RSUs

M&A / Property Mar 02, 2026 · 08:30

BioSyent Announces Closing of the Acquisition of Oral Science Inc.

M&A / Property